News | January 13, 2025
Aragen secures $100 million investment from Quadria Capital
Investment will fund expansion to meet rising demand for CRDMO services
Investment will fund expansion to meet rising demand for CRDMO services
Acquisition expands high-value medical platform
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
Brings together industry experts to discuss preventive steps to protect pigs from African swine fever and best practises for pig farm management
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Subscribe To Our Newsletter & Stay Updated
